


Checklist for Prescribers:

Initiation of ^{Pr} MINT-EMTRICITABINE/TENOFOVIR for Pre-exposure Prophylaxis (PrEP) in adults at high risk of HIV-1 infection



Instructions:

Complete checklist at each visit and file in individual's medical record.

I have completed the following prior to prescribing MINT-EMTRICITABINE/TENOFOVIR for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication:

LAB TESTS / EVALUATION

- ☐ Completed high risk evaluation of uninfected individual
- ☐ Confirmed a negative HIV-1 test immediately prior to initiating MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication
 - If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by Health Canada as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: MINT-EMTRICITABINE/ TENOFOVIR for a PrEP indication is contraindicated in individuals with unknown HIV-1 status or who are HIV-1 positive)
- ☐ Performed HBV screening test
- ☐ Confirmed estimated creatinine clearance (CrCl) ≥ 60 mL/min prior to initiation and periodically during treatment. In patients at risk for renal dysfunction, assess estimated CrCl, serum phosphorus, urine glucose and urine protein before initiation of MINT-EMTRICITABINE/TENOFOVIR and periodically while MINT-EMTRICITABINE/TENOFOVIR is being used. If a decrease in estimated CrCl is observed in uninfected individuals while using MINT-EMTRICITABINE/ TENOFOVIR for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use
- ☐ Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or HBV medications
- ☐ Evaluated risk/benefit for women who may be pregnant or may want to become pregnant

COUNSELING / FOLLOW-UP

- ☐ Discussed known safety risks with use of MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication
- ☐ Counseled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking MINT-EMTRICITABINE/TENOFOVIR for PrEP to reconfirm HIV-1-negative status
- ☐ Discussed the importance of discontinuing MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants
- ☐ Counseled on the importance of adherence to daily dosing schedule
- ☐ Counseled that MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication should be used only as part of a comprehensive prevention strategy
- ☐ Educated on practicing safer sex consistently and using condoms correctly
- ☐ Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)
- ☐ Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission
- ☐ Offered HBV vaccination as appropriate
- ☐ Provided education on where information about MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication can be accessed
- ☐ Discussed potential adverse reactions
- ☐ Reviewed the MINT-EMTRICITABINE/TENOFOVIR Uninfected Individual Safety Brochure with the uninfected individual at high risk